UA114286C2 - Спосіб лікування staphylococcus aureus - Google Patents

Спосіб лікування staphylococcus aureus

Info

Publication number
UA114286C2
UA114286C2 UAA201310981A UAA201310981A UA114286C2 UA 114286 C2 UA114286 C2 UA 114286C2 UA A201310981 A UAA201310981 A UA A201310981A UA A201310981 A UAA201310981 A UA A201310981A UA 114286 C2 UA114286 C2 UA 114286C2
Authority
UA
Ukraine
Prior art keywords
staphylococcus aureus
against staphylococcus
compositions
methods
mammal
Prior art date
Application number
UAA201310981A
Other languages
English (en)
Inventor
Майкл Р. Йіман
Майкл Р. Йиман
Джр. Едвардс Джон Е.
Джр. Эдвардс Джон Э.
Скотт Дж. Філлер
Скотт Дж. Филлер
Ашраф С. Ібрагім
Ашраф С. Ибрагим
Юе Фу
Джр. Хеннесі Джон П.
Джр. Хеннеси Джон П.
Original Assignee
Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка"
ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"
Лос-Анджелес Біомедікал Ресьорч Інститут Ет Харбор-Укла Медікал Центер
Лос-Анджелес Биомедикал Ресёрч Институт Эт Харбор-Укла Медикал Центер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка", ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика", Лос-Анджелес Біомедікал Ресьорч Інститут Ет Харбор-Укла Медікал Центер, Лос-Анджелес Биомедикал Ресёрч Институт Эт Харбор-Укла Медикал Центер filed Critical Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка"
Publication of UA114286C2 publication Critical patent/UA114286C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Винахід стосується способу лікування ссавця, що має інфекцію шкіри або м'яких тканин, що викликається Staphylococcus aureus, який включає введення згаданому ссавцю імуногенної кількості вакцини, яка включає виділений білок Als3p, що складається з амінокислотної послідовності SEQ ID NO: 2 та фармацевтично прийнятного середовища.
UAA201310981A 2011-07-22 2012-07-20 Спосіб лікування staphylococcus aureus UA114286C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161510896P 2011-07-22 2011-07-22
PCT/US2012/000328 WO2013015831A1 (en) 2011-07-22 2012-07-20 Methods and compositions for vaccinating against staphylococcus aureus

Publications (1)

Publication Number Publication Date
UA114286C2 true UA114286C2 (uk) 2017-05-25

Family

ID=47601425

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201310981A UA114286C2 (uk) 2011-07-22 2012-07-20 Спосіб лікування staphylococcus aureus

Country Status (12)

Country Link
US (1) US10653757B2 (uk)
EP (1) EP2734229B1 (uk)
JP (1) JP2014521605A (uk)
CN (1) CN103998056B (uk)
AU (1) AU2012287513A1 (uk)
BR (1) BR112014001409A2 (uk)
CA (1) CA2842626A1 (uk)
EA (1) EA035513B1 (uk)
ES (1) ES2716800T3 (uk)
GE (1) GEP201706766B (uk)
UA (1) UA114286C2 (uk)
WO (1) WO2013015831A1 (uk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
CN103998056B (zh) 2011-07-22 2017-09-12 诺瓦蒂格姆疗法有限公司 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
WO2014153241A1 (en) * 2013-03-14 2014-09-25 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
AU2014240165A1 (en) * 2013-03-14 2015-10-01 Rongfu Wang Methods and compositions for modulating regulatory T cell function
AU2014227748B2 (en) * 2013-03-15 2019-02-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
EP3426287A4 (en) * 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center METHODS AND KITS FOR USE IN THE PREVENTION AND TREATMENT OF VULVO-VAGINAL CANDIDOSIS
CN105713096B (zh) * 2016-03-29 2019-01-01 黑龙江八一农垦大学 一种预防金黄色葡萄球菌感染的att融合蛋白的制备及应用
WO2019199279A1 (en) * 2018-04-10 2019-10-17 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods of treatment for candida auris infections
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980000412A1 (en) 1978-08-24 1980-03-20 N Gilmour Pasteurellosis vaccines
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
EP1624068A1 (en) 1993-06-01 2006-02-08 Life Technologies Inc. Genetic immunization with cationic lipids
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
AU2657495A (en) 1994-05-23 1995-12-18 Research And Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
SK282004B6 (sk) 1995-06-07 2001-10-08 Pfizer Inc. Použitie živých sporozoitov alebo merozoitov rodu eimeria na výrobu očkovacej látky na in ovo očkovanie domestikovaných vtákov proti kokcidióze
CA2255669A1 (en) 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) * 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
WO2003047336A2 (en) 2001-11-30 2003-06-12 Abgenix, Inc. TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES
US7250286B2 (en) 2002-05-21 2007-07-31 Schering-Plough Corporation Methods for the in vitro culture of Sporozoea sp. and uses thereof
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
WO2004043407A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
CA2546195A1 (en) * 2003-11-21 2005-06-02 Pfizer Products Inc. The use of anti biotics as vaccine adjuvants
WO2005060713A2 (en) 2003-12-19 2005-07-07 Inhibitex, Inc. Method of inhibiting candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
JP5551933B2 (ja) 2006-04-17 2014-07-16 シェーリング−プラウ・リミテッド 組み換え弱毒化Ｃｌｏｓｔｒｉｄｉｕｍ生物体およびワクチン
WO2008147847A1 (en) 2007-05-22 2008-12-04 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
MX2010012869A (es) 2008-05-29 2010-12-14 Intervet Int Bv Vacunas contra coccidiosis.
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
PE20110023A1 (es) * 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
CN102574895B (zh) 2009-07-03 2014-06-11 加州大学洛杉矶海滨分校医学中心的洛杉矶生物医学研究所 作为针对念珠菌的主动和被动免疫接种的靶标的hyr1
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
CN103998056B (zh) 2011-07-22 2017-09-12 诺瓦蒂格姆疗法有限公司 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center METHODS AND KITS FOR USE IN THE PREVENTION AND TREATMENT OF VULVO-VAGINAL CANDIDOSIS

Also Published As

Publication number Publication date
EA035513B1 (ru) 2020-06-29
CN103998056B (zh) 2017-09-12
JP2014521605A (ja) 2014-08-28
US10653757B2 (en) 2020-05-19
US20150273031A1 (en) 2015-10-01
EA201391200A1 (ru) 2014-05-30
CN103998056A (zh) 2014-08-20
AU2012287513A8 (en) 2014-06-19
CA2842626A1 (en) 2013-01-31
WO2013015831A1 (en) 2013-01-31
AU2012287513A1 (en) 2014-03-13
EP2734229A4 (en) 2015-01-21
ES2716800T3 (es) 2019-06-17
GEP201706766B (en) 2017-10-25
BR112014001409A2 (pt) 2017-07-11
EP2734229B1 (en) 2019-01-02
EP2734229A1 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
UA114286C2 (uk) Спосіб лікування staphylococcus aureus
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
GB201101665D0 (en) Immunogenic compositions
CR11731A (es) Composiciones y procedimientos para su preparación y uso
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CA2763359C (en) New human rotavirus strains and vaccines
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
MX357538B (es) Vacunas para meningococo de serogrupo x.
EP2528931A4 (en) CYCLOVIRUS AND USE METHOD THEREFOR
MX2017011322A (es) Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus.
MX2016001695A (es) Composiciones inmunogenas de combinacion.
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
WO2012078051A3 (en) IPN Vaccine
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
MX2012012479A (es) Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.